Mirae Asset Global ETFs Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.9M	Buy	81,325 +1,224	+2%	+$417K	0.04%	397
2025 Q4	$31.9M	Buy	80,101 +69,430	+651%	+$30.7M	0.05%	348
2025 Q3	$4.86M	Sell	10,671 -887	-8%	-$361K	0.01%	817
2025 Q2	$3.76M	Sell	11,558 -2,395	-17%	-$663K	0.01%	826
2025 Q1	$3.76M	Sell	13,953 -778	-5%	-$200K	0.01%	851
2024 Q4	$3.47M	Sell	14,731 -11,081	-43%	-$2.91M	0.01%	879
2024 Q3	$7.1M	Sell	25,812 -5,481	-18%	-$1.43M	0.02%	669
2024 Q2	$7.62M	Buy	+31,293	New	+$4.94M	0.02%	621

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ALNY Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 1.5% in Q1 2026, buying an estimated $417K and bringing the position to 81,325 shares worth $26.9M. The position accounts for 0.04% of the portfolio, ranked #397.

Mirae Asset Global ETFs Holdings first reported a position in ALNY in Q2 2024 and has held it in 8 quarters since. The position peaked at $31.9M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Mirae Asset Global ETFs Holdings held 81,325 shares of Alnylam Pharmaceuticals worth $26.9M as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 1,224 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $417K.
Alnylam Pharmaceuticals made up 0.04% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #397 holding.
Mirae Asset Global ETFs Holdings first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Alnylam Pharmaceuticals position peaked at $31.9M in Q4 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.